PolyPid (PYPD) Projected to Post Quarterly Earnings on Wednesday

PolyPid (NASDAQ:PYPD) is expected to be posting its Q4 2025 results before the market opens on Wednesday, February 11th. Analysts expect the company to announce earnings of ($0.34) per share for the quarter. Interested persons may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Wednesday, February 11, 2026 at 8:30 AM ET.

PolyPid (NASDAQ:PYPD) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($0.37) EPS for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.17.

PolyPid Stock Down 2.7%

PYPD stock opened at $4.74 on Wednesday. PolyPid has a twelve month low of $2.30 and a twelve month high of $5.12. The firm has a market capitalization of $75.37 million, a PE ratio of -1.59 and a beta of 1.52. The stock has a 50-day simple moving average of $4.27 and a two-hundred day simple moving average of $3.77.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in PolyPid stock. BNP Paribas Financial Markets boosted its position in shares of PolyPid Ltd. (NASDAQ:PYPD) by 56.1% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 9,734 shares of the company’s stock after purchasing an additional 3,500 shares during the period. BNP Paribas Financial Markets owned about 0.06% of PolyPid worth $32,000 as of its most recent SEC filing. 26.47% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on PYPD shares. Weiss Ratings restated a “sell (d-)” rating on shares of PolyPid in a research note on Monday, December 29th. Wall Street Zen upgraded PolyPid from a “sell” rating to a “hold” rating in a report on Sunday, November 16th. Citigroup restated a “market outperform” rating on shares of PolyPid in a report on Monday, December 1st. Finally, Roth Mkm dropped their target price on PolyPid from $10.00 to $9.00 and set a “buy” rating on the stock in a report on Thursday, November 13th. Five investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $12.25.

About PolyPid

PolyPid Ltd is a clinical‐stage biotechnology company focused on polymer‐based drug delivery technologies designed to enhance the performance of therapeutic agents at mucosal surfaces. Leveraging its proprietary Mucoadhesive & Mucus‐Penetrating (MMP) platform, PolyPid develops long‐acting formulations for ocular, oral and pulmonary indications. Its lead candidates include OncoTears and OralTear, therapies targeting dry eye and dry mouth conditions, respectively, as well as Paclical, a polymer‐formulated paclitaxel designed to improve tolerability and antitumor activity in oncology patients.

Founded in 2003 and headquartered in Jerusalem, Israel, PolyPid has assembled an international patent portfolio covering key markets in North America, Europe and Asia.